T he pharmaceutical company Cortexyme announced that the first group of participants has been dosed in the Phase 1 clinical trial of its lead compound, COR388, for the treatment of Alzheimer’s disease.

Because no new successful developments have emerged in Alzheimer’s therapeutics in the last 15 years, researchers have been trying to discover new and innovative ways to treat the disease.

“The failure of so many large clinical trials targeting

amyloid beta over the last decade illustrates

the urgent need for new therapeutic targets,

generated by scientifically sound hypotheses

of Alzheimer’s pathogenesis [disease development],

to guide development of novel and safe therapeutics,

Samer Kaba, Cortexyme’s chief medical officer